Compare Stocks → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ENTXNASDAQ:LIFENASDAQ:ONVONASDAQ:OTLK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$2.46-3.1%$1.91$0.52▼$3.35$70.85M1.63206,553 shs154,644 shsLIFEaTyr Pharma$1.69-1.7%$1.75$1.08▼$2.70$114.56M1.27422,788 shs223,763 shsONVOOrganovo$0.92-6.1%$1.03$0.85▼$2.05$9.54M0.873.00 million shs148,114 shsOTLKOutlook Therapeutics$7.58-1.9%$8.49$4.00▼$40.60$110.61M0.28245,950 shs392,655 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+3.67%+21.53%+12.89%+182.22%+182.38%LIFEaTyr Pharma+1.78%+7.50%0.00%-12.69%-23.89%ONVOOrganovo+2.72%+3.76%-5.90%+9.57%-48.10%OTLKOutlook Therapeutics-3.37%-9.06%-16.52%-6.67%-67.25%Charles Payne Demystifies Options (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTXEntera Bio1.4541 of 5 stars3.55.00.00.00.60.00.0LIFEaTyr Pharma1.9477 of 5 stars3.43.00.00.02.61.70.0ONVOOrganovo0.2147 of 5 stars0.03.00.00.01.10.01.3OTLKOutlook Therapeutics1.8293 of 5 stars3.42.00.00.01.91.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio3.00Buy$10.00306.50% UpsideLIFEaTyr Pharma2.75Moderate Buy$23.671,300.39% UpsideONVOOrganovoN/AN/AN/AN/AOTLKOutlook Therapeutics2.88Moderate Buy$46.43512.47% UpsideCurrent Analyst RatingsLatest OTLK, ENTX, ONVO, and LIFE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/3/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/2/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$130K544.98N/AN/A$0.36 per share6.83LIFEaTyr Pharma$350K333.22N/AN/A$1.22 per share1.39ONVOOrganovo$370K25.07N/AN/A$1.76 per share0.53OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$8.89M-$0.31N/AN/AN/AN/A-101.78%-83.90%5/10/2024 (Estimated)LIFEaTyr Pharma-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%8/14/2024 (Estimated)ONVOOrganovo-$17.26M-$2.17N/AN/AN/AN/A-182.88%-138.52%7/11/2024 (Estimated)OTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/16/2024 (Confirmed)Latest OTLK, ENTX, ONVO, and LIFE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2024N/AOTLKOutlook Therapeutics-$0.88N/A+$0.88N/AN/AN/A 5/2/2024Q1 2024LIFEaTyr Pharma-$0.24-$0.23+$0.01-$0.23$0.11 million$0.24 million 3/14/2024Q4 2023LIFEaTyr Pharma-$0.23-$0.25-$0.02-$0.25N/AN/A3/8/2024Q4 2023ENTXEntera Bio-$0.08-$0.07+$0.01-$0.07N/AN/A2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A10.3210.32LIFEaTyr Pharma0.026.076.07ONVOOrganovoN/A3.673.67OTLKOutlook TherapeuticsN/A0.440.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%LIFEaTyr Pharma61.72%ONVOOrganovo8.23%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio8.90%LIFEaTyr Pharma3.70%ONVOOrganovo5.00%OTLKOutlook Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio1728.80 millionN/AOptionableLIFEaTyr Pharma5669.01 million66.46 millionOptionableONVOOrganovo1810.04 million9.54 millionOptionableOTLKOutlook Therapeutics2413.01 million12.32 millionOptionableOTLK, ENTX, ONVO, and LIFE HeadlinesSourceHeadlineOutlook Therapeutics (OTLK) to Release Quarterly Earnings on Thursdaymarketbeat.com - May 10 at 8:31 AMOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcastfinance.yahoo.com - May 9 at 9:19 AMOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcastglobenewswire.com - May 9 at 8:45 AMOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Moderate Buy" from Brokeragesamericanbankingnews.com - May 8 at 4:36 AMGlobal $320 Billion Aviation Fuel Market Outlook, 2024-2029: Emission Reduction Initiatives, Rising Air Freight Demand, Emerging Marketsfinance.yahoo.com - May 3 at 3:15 AMHow to fix Microsoft Outlookmsn.com - May 3 at 3:15 AMOutlook Therapeutics® to Present at the Retina World Congress 2024globenewswire.com - May 2 at 9:05 AMEconomic Outlook Conference to be held Monday on CWU campuscwu.edu - May 1 at 8:40 PMCEOs and Investors Navigate Shifting Economic Terrain: Outlook Revealed in EY CEO Pulse Surveynews.europawire.eu - May 1 at 3:40 PMOutlook News Wrap, May 1: 100 Schools In Delhi Get Bomb Threat, Heatwave Alert Issued Amid 47 Deg Temperature, Split In Godrej & Moreoutlookindia.com - May 1 at 9:56 AMQ1 2024 CA Auto Outlook: Tesla registrations drop; Sales slip 7.8% YTDivpressonline.com - April 30 at 2:18 PMNatural Gas News: Freeport LNG Resumption Brightens Outlookfxempire.com - April 29 at 1:15 PMOutlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcaseglobenewswire.com - April 29 at 9:00 AMThese 5 programs are way better than Microsoft Outlookmsn.com - April 29 at 8:15 AMHCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 Outlookusnews.com - April 29 at 8:15 AMBest's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation Councilfinance.yahoo.com - April 29 at 1:28 AMBulgaria's Eurozone Aspirations: Fitch Ratings Affirms Positive Outlooknovinite.com - April 27 at 7:18 AMOutlook Magazine's Reporters Guarantee: Editor's Exclusiveoutlookindia.com - April 27 at 2:18 AMOutlook man accused of dragging girlfriend with his caryakimaherald.com - April 27 at 2:18 AMGlobal Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036finance.yahoo.com - April 26 at 4:17 PMHow to Use Copilot in Outlookmsn.com - April 26 at 4:17 PMOutlook's Next Issue: Inside The Election Cauldronoutlookindia.com - April 26 at 4:17 PMMedia advisory - OECD Economic Outlook 2024oecd.org - April 26 at 6:16 AMBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positivefinance.yahoo.com - April 22 at 1:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEntera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.